Evidence map›Paper›PMID 29456506›Full record

ReviewFrontiers in pharmacology2018

Therapeutic Effects of a Traditional Chinese Medicine Formula Plus Tamoxifen vs. Tamoxifen for the Treatment of Mammary Gland Hyperplasia: A Meta-Analysis of Randomized Trials.

Hao-Tian Li, Hong-Hong Liu, Yu-Xue Yang, Tao Wang, Xue-Lin Zhou, Yang Yu, Su-Na Li, Yi Zheng, Ping Zhang, Rui-Lin Wang and 5 more

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Glycomics: Immunoglobulin GOmics : a journal of integrative biology · 2020
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Hao-Tian LiDepartment of Pharmacy, 302 Military Hospital of China, Beijing, China.
Hong-Hong LiuInternational Center for Liver Disease Treatment, 302 Military Hospital of China, Beijing, China.
Yu-Xue YangCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Tao WangCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Xue-Lin ZhouDepartment of Pharmacy, 302 Military Hospital of China, Beijing, China.
Yang YuDepartment of Traditional Chinese Medicine, First Affiliated Hospital of Chinese PLA General Hospital, Beijing, China.
Su-Na LiDepartment of Traditional Chinese Medicine, First Affiliated Hospital of Chinese PLA General Hospital, Beijing, China.
Yi ZhengDepartment of Traditional Chinese Medicine, First Affiliated Hospital of Chinese PLA General Hospital, Beijing, China.
Ping ZhangIntegrative Medical Center, 302 Military Hospital of China, Beijing, China.
Rui-Lin WangIntegrative Medical Center, 302 Military Hospital of China, Beijing, China.
Jian-Yu LiIntegrative Medical Center, 302 Military Hospital of China, Beijing, China.
Shi-Zhang WeiDepartment of Pharmacy, 302 Military Hospital of China, Beijing, China.
Kun LiDepartment of Pharmacy, 302 Military Hospital of China, Beijing, China.
Peng-Yan LiChina Military Institute of Chinese Medicine, 302 Military Hospital of China, Beijing, China.
Li-Qi QianDepartment of Traditional Chinese Medicine, First Affiliated Hospital of Chinese PLA General Hospital, Beijing, China.
302 Military Hospital of China · CNFirst Affiliated Hospital of Chinese PLA General Hospital · CNChengdu University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a common disorder that accounts for over 70% of all breast disease cases, mammary gland hyperplasia (MGH) causes a severe problem for the quality of patients' life, and confers an increased risk of breast carcinoma. However, the etiology and pathogenesis of MGH remain unclear, and the safety and efficacy of current western drug therapy for MGH still need to be improved. Therefore, a meta-analysis was conducted by our team to determine whether a TCM formula named Ru-Pi-Xiao in combination with tamoxifen or Ru-Pi-Xiao treated alone can show more prominent therapeutic effects against MGH with fewer adverse reactions than that of tamoxifen. Studies published before June 2017 were searched based on standardized searching rules in several mainstream medical databases. A total of 27 articles with 4,368 patients were enrolled in this meta-analysis. The results showed that the combination of Ru-Pi-Xiao and tamoxifen could exhibit better therapeutic effects against MGH than that of tamoxifen (OR: 3.79; 95% CI: 3.09-4.65;

Indexed as

breast lumpefficacy and safetyhormonal parametersmammary gland hyperplasiameta-analysisRu-Pi-Xiaotamoxifen

Identifiers

PMID29456506
PMCPMC5801403
OpenAlexW2789462798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.